Experimental drug aims to keep myeloma at bay after transplant
NCT ID NCT05065047
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This early-phase study tested whether the drug belantamab mafodotin (Blenrep) could help prevent multiple myeloma from returning after a stem cell transplant. Six participants with relapsed or refractory myeloma received the drug as maintenance therapy. The study focused on safety and pain changes, but was terminated early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.